[1]

Tran L, Xiao JF, Agarwal N, Duex JE, Theodorescu D. 2021. Advances in bladder cancer biology and therapy. Nature Reviews Cancer 21:104−121

doi: 10.1038/s41568-020-00313-1
[2]

Lenis AT, Lec PM, Chamie K, Mshs MD. 2020. Bladder Cancer: A Review. JAMA 324:1980−1991

doi: 10.1001/jama.2020.17598
[3]

Dinney CPN, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, et al. 2004. Focus on bladder cancer. Cancer Cell 6:111−116

doi: 10.1016/j.ccr.2004.08.002
[4]

Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström PU, et al. 2016. Bladder cancer. The Lancet 388:2796−2810

doi: 10.1016/S0140-6736(16)30512-8
[5]

Knowles MA, Hurst CD. 2015. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nature Reviews Cancer 15:25−41

doi: 10.1038/nrc3817
[6]

Galsky MD, Arija JÁA, Bamias A, Davis ID, De Santis M, et al. 2020. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. The Lancet 395:1547−1557

doi: 10.1016/S0140-6736(20)30230-0
[7]

Patel VG, Oh WK, Galsky MD. 2020. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA: A Cancer Journal for Clinicians 70:404−423

doi: 10.3322/caac.21631
[8]

Dyrskjøt L, Hansel DE, Efstathiou JA, Knowles MA, Galsky MD, et al. 2023. Bladder cancer. Nature Reviews Disease Primers 9:58

doi: 10.1038/s41572-023-00468-9
[9]

Weinstein JN, Akbani R, Broom BM, Wang W, Verhaak RGW, et al. 2014. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507:315−322

doi: 10.1038/nature12965
[10]

Ross JS, Wang K, Gay LM, Al-Rohil RN, Nazeer T, et al. 2014. A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma. Clinical Cancer Research 20:68−75

doi: 10.1158/1078-0432.CCR-13-1992
[11]

Kim J, Akbani R, Creighton CJ, Lerner SP, Weinstein JN, et al. 2015. Invasive bladder cancer: genomic insights and therapeutic promise. Clinical Cancer Research 21:4514−4524

doi: 10.1158/1078-0432.CCR-14-1215
[12]

Huan J, Grivas P, Birch J, Hansel DE. 2022. Emerging roles for mammalian target of rapamycin (mTOR) complexes in bladder cancer progression and therapy. Cancers 14:1555

doi: 10.3390/cancers14061555
[13]

Rubenstein CS, Gard JMC, Wang M, McGrath JE, Ingabire N, et al. 2019. Gene editing of α6 integrin inhibits muscle invasive networks and increases cell-cell biophysical properties in prostate cancer. Cancer Research 79:4703−4714

doi: 10.1158/0008-5472.CAN-19-0868
[14]

Harryman WL, Marr KD, Hernandez-Cortes D, Nagle RB, Garcia JGN, et al. 2021. Cohesive cancer invasion of the biophysical barrier of smooth muscle. Cancer and Metastasis Reviews 40:205−219

doi: 10.1007/s10555-020-09950-2
[15]

Szarvas T, vom Dorp F, Ergün S, Rübben H. 2011. Matrix metalloproteinases and their clinical relevance in urinary bladder cancer. Nature Reviews Urology 8:241−254

doi: 10.1038/nrurol.2011.44
[16]

Andersson KE, Arner A. 2004. Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiological Reviews 84:935−986

doi: 10.1152/physrev.00038.2003
[17]

Liu M, Gomez D. 2019. Smooth muscle cell phenotypic diversity. Arteriosclerosis, Thrombosis, and Vascular Biology 39:1715−1723

doi: 10.1161/ATVBAHA.119.312131
[18]

Allahverdian S, Chaabane C, Boukais K, Francis GA, Bochaton-Piallat ML. 2018. Smooth muscle cell fate and plasticity in atherosclerosis. Cardiovascular Research 114:540−550

doi: 10.1093/cvr/cvy022
[19]

Feil S, Fehrenbacher B, Lukowski R, Essmann F, Schulze-Osthoff K, et al. 2014. Transdifferentiation of vascular smooth muscle cells to macrophage-like cells during atherogenesis. Circulation Research 115:662−667

doi: 10.1161/CIRCRESAHA.115.304634
[20]

Hong X, Margariti A, Le Bras A, Jacquet L, Kong W, et al. 2017. Transdifferentiated human vascular smooth muscle cells are a new potential cell source for endothelial regeneration. Scientific Reports 7:5590

doi: 10.1038/s41598-017-05665-7
[21]

Murgai M, Ju W, Eason M, Kline J, Beury DW, et al. 2017. KLF4-dependent perivascular cell plasticity mediates pre-metastatic niche formation and metastasis. Nature Medicine 23:1176−1190

doi: 10.1038/nm.4400
[22]

Cao L, Wu G, Zhu J, Tan Z, Shi D, et al. 2019. Genotoxic stress-triggered β-catenin/JDP2/PRMT5 complex facilitates reestablishing glutathione homeostasis. Nature Communications 10:3761

doi: 10.1038/s41467-019-11696-7
[23]

Jiang S, Wang J, Yang C, Tan R, Hou J, et al. 2019. Continuous culture of urine-derived bladder cancer cells for precision medicine. Protein & Cell 10:902−907

doi: 10.1007/s13238-019-0649-5
[24]

Naito T, Higuchi T, Shimada Y, Kakinuma C. 2020. An improved mouse orthotopic bladder cancer model exhibiting progression and treatment response characteristics of human recurrent bladder cancer. Oncology Letters 19:833−839

doi: 10.3892/ol.2019.11172
[25]

Li C, Yan R, Bao J, Yuan G, Feng Y, et al. 2006. Characterization of a novel transplantable orthotopic murine xenograft model of a human bladder transitional cell tumor (BIU-87). Cancer Biology & Therapy 5:394−398

doi: 10.4161/cbt.5.4.2509
[26]

Lorenzatti Hiles G, Cates AL, El-Sawy L, Day KC, Broses LJ, et al. 2019. A surgical orthotopic approach for studying the invasive progression of human bladder cancer. Nature Protocols 14:738−755

doi: 10.1038/s41596-018-0112-8
[27]

Hayashi T, Gust KM, Wyatt AW, Goriki A, Jäger W, et al. 2016. Not all NOTCH is created equal: the oncogenic role of NOTCH2 in bladder cancer and its implications for targeted therapy. Clinical Cancer Research 22:2981−2992

doi: 10.1158/1078-0432.CCR-15-2360
[28]

Hu C, Liu Y, Lin Y, Liang JK, Zhong WW, et al. 2018. Intravenous injections of the oncolytic virus M1 as a novel therapy for muscle-invasive bladder cancer. Cell Death & Disease 9:274

doi: 10.1038/s41419-018-0325-3
[29]

Liu X, Zhang Y, Chen Y, Li M, Zhou F, et al. 2017. In situ capture of chromatin interactions by biotinylated dCas9. Cell 170:1028−1043.e19

doi: 10.1016/j.cell.2017.08.003
[30]

Li G, Wang D, Zhai Y, Pan C, Zhang J, et al. 2024. Glycometabolic reprogramming-induced XRCC1 lactylation confers therapeutic resistance in ALDH1A3-overexpressing glioblastoma. Cell Metabolism 36:1696−1710.e10

doi: 10.1016/j.cmet.2024.07.011
[31]

Weidner N. 1995. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Research and Treatment 36:169−180

doi: 10.1007/BF00666038
[32]

Monteiro-Reis S, Ferreira JPS, Pires RA, Lobo J, Carvalho JA, et al. 2023. Bladder wall stiffness after cystectomy in bladder cancer patients: a preliminary study. Cancers 15:359

doi: 10.3390/cancers15020359
[33]

Xu Y, Zhang H, Chen Y, Pober JS, Zhou M, et al. 2024. SRF SUMOylation modulates smooth muscle phenotypic switch and vascular remodeling. Nature Communications 15:6919

doi: 10.1038/s41467-024-51350-5
[34]

Salmon M, Gomez D, Greene E, Shankman L, Owens GK. 2012. Cooperative binding of KLF4, pELK-1, and HDAC2 to a G/C repressor element in the SM22α promoter mediates transcriptional silencing during SMC phenotypic switching in vivo. Circulation Research 111:685−696

doi: 10.1161/CIRCRESAHA.112.269811
[35]

Reddy A, Winther S, Tran N, Xiao H, Jakob J, et al. 2024. Monocarboxylate transporters facilitate succinate uptake into brown adipocytes. Nature Metabolism 6:567−577

doi: 10.1038/s42255-024-00981-5
[36]

Gudgeon N, Munford H, Bishop EL, Hill J, Fulton-Ward T, et al. 2022. Succinate uptake by T cells suppresses their effector function via inhibition of mitochondrial glucose oxidation. Cell Reports 40:111193

doi: 10.1016/j.celrep.2022.111193
[37]

Peruzzotti-Jametti L, Bernstock JD, Vicario N, Costa ASH, Kwok CK, et al. 2018. Macrophage-derived extracellular succinate licenses neural stem cells to suppress chronic neuroinflammation. Cell Stem Cell 22:355−368.e13

doi: 10.1016/j.stem.2018.01.020
[38]

Reddy A, Bozi LHM, Yaghi OK, Mills EL, Xiao H, et al. 2020. pH-gated succinate secretion regulates muscle remodeling in response to exercise. Cell 183:62−75.e17

doi: 10.1016/j.cell.2020.08.039
[39]

Meng S, Zhou G, Gu Q, Chanda PK, Ospino F, et al. 2016. Transdifferentiation requires iNOS activation: role of RING1A S-nitrosylation. Circulation Research 119:e129−e138

doi: 10.1161/CIRCRESAHA.116.308263
[40]

Mossa AH, Velasquez Flores M, Cammisotto PG, Campeau L. 2017. Succinate, increased in metabolic syndrome, activates GPR91 receptor signaling in urothelial cells. Cellular Signalling 37:31−39

doi: 10.1016/j.cellsig.2017.05.014
[41]

Ren R, Fan Y, Peng Z, Wang S, Jiang Y, et al. 2022. Characterization and perturbation of CTCF-mediated chromatin interactions for enhancing myogenic transdifferentiation. Cell Reports 40:111206

doi: 10.1016/j.celrep.2022.111206
[42]

Xu Q, Sun J, Holden CM, Neto HCF, Wang T, et al. 2024. Cellular communication network factor 2 regulates smooth muscle cell transdifferentiation and lipid accumulation in atherosclerosis. Cardiovascular Research 120:2191−2207

doi: 10.1093/cvr/cvae215
[43]

Stomberski CT, Hess DT, Stamler JS. 2019. Protein S-nitrosylation: determinants of specificity and enzymatic regulation of S-nitrosothiol-based signaling. Antioxidants & Redox Signaling 30:1331−1351

doi: 10.1089/ars.2017.7403
[44]

Lin Z, Zhao S, Li X, Miao Z, Cao J, et al. 2023. Cathepsin B S-nitrosylation promotes ADAR1-mediated editing of its own mRNA transcript via an ADD1/MATR3 regulatory axis. Cell Research 33:546−561

doi: 10.1038/s41422-023-00812-4
[45]

Guo Y, Wen J, He A, Qu C, Peng Y, et al. 2023. iNOS contributes to heart failure with preserved ejection fraction through mitochondrial dysfunction and Akt S-nitrosylation. Journal of Advanced Research 43:175−186

doi: 10.1016/j.jare.2022.03.003
[46]

Sha Y, Marshall HE. 2012. S-nitrosylation in the regulation of gene transcription. Biochimica et Biophysica Acta (BBA) - General Subjects 1820:701−711

doi: 10.1016/j.bbagen.2011.05.008
[47]

Liu X, Zhao G, Sun S, Fan C, Feng X, et al. 2022. Biosynthetic pathway and metabolic engineering of succinic acid. Frontiers in Bioengineering and Biotechnology 10:843887

doi: 10.3389/fbioe.2022.843887
[48]

Fernández-Veledo S, Ceperuelo-Mallafré V, Vendrell J. 2021. Rethinking succinate: an unexpected hormone-like metabolite in energy homeostasis. Trends in Endocrinology & Metabolism 32:680−692

doi: 10.1016/j.tem.2021.06.003
[49]

Zhang J, Wang YT, Miller JH, Day MM, Munger JC, et al. 2018. Accumulation of succinate in cardiac ischemia primarily occurs via canonical krebs cycle activity. Cell Reports 23:2617−2628

doi: 10.1016/j.celrep.2018.04.104
[50]

Bisbach CM, Hass DT, Robbings BM, Rountree AM, Sadilek M, et al. 2020. Succinate can shuttle reducing power from the hypoxic retina to the O2-rich pigment epithelium. Cell Reports 31:107606

doi: 10.1016/j.celrep.2020.107606
[51]

Chouchani ET, Pell VR, Gaude E, Aksentijević D, Sundier SY, et al. 2014. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature 515:431−435

doi: 10.1038/nature13909
[52]

Taegtmeyer H. 1978. Metabolic responses to cardiac hypoxia. Increased production of succinate by rabbit papillary muscles. Circulation Research 43:808−815

doi: 10.1161/01.res.43.5.808
[53]

Spinelli JB, Rosen PC, Sprenger HG, Puszynska AM, Mann JL, et al. 2021. Fumarate is a terminal electron acceptor in the mammalian electron transport chain. Science 374:1227−1237

doi: 10.1126/science.abi7495
[54]

Borst P. 2020. The malate-aspartate shuttle (Borst cycle): How it started and developed into a major metabolic pathway. IUBMB Life 72:2241−2259

doi: 10.1002/iub.2367
[55]

Yang H, Zhou L, Shi Q, Zhao Y, Lin H, et al. 2015. SIRT3-dependent GOT2 acetylation status affects the malate-aspartate NADH shuttle activity and pancreatic tumor growth. The EMBO Journal 34:1110−1125

doi: 10.15252/embj.201591041
[56]

Bulusu V, Jayaraman V, Balaram H. 2011. Metabolic fate of fumarate, a side product of the purine salvage pathway in the intraerythrocytic stages of Plasmodium falciparum. Journal of Biological Chemistry 286:9236−9245

doi: 10.1074/jbc.M110.173328
[57]

Watts RWE. 1983. Some regulatory and integrative aspects of purine nucleotide biosynthesis and its control: an overview. Advances in Enzyme Regulation 21:33−51

doi: 10.1016/0065-2571(83)90007-9
[58]

Taeusch HW, Smith BT. 1987. Surfactant sufficiency for immature infants-prenatal induction vs. postnatal treatment. European Journal of Respiratory Diseases Supplement 153:249−254
[59]

Banerjee R, Kumar R. 2022. Gas regulation of complex II reversal via electron shunting to fumarate in the mammalian ETC. Trends in Biochemical Sciences 47:689−698

doi: 10.1016/j.tibs.2022.03.011
[60]

Massague J, Seoane J, Wotton D. 2005. Smad transcription factors. Genes & Development 19:2783−2810

doi: 10.1101/gad.1350705
[61]

Schmierer B, Hill CS. 2007. TGFβ–SMAD signal transduction: molecular specificity and functional flexibility. Nature Reviews Molecular Cell Biology 8:970−982

doi: 10.1038/nrm2297
[62]

Moustakas A, Souchelnytskyi S, Heldin CH. 2001. Smad regulation in TGF-β signal transduction. Journal of Cell Science 114:4359−4369

doi: 10.1242/jcs.114.24.4359
[63]

Colak S, Ten Dijke P. 2017. Targeting TGF-β signaling in cancer. Trends in Cancer 3:56−71

doi: 10.1016/j.trecan.2016.11.008
[64]

Bedford MT, Richard S. 2005. Arginine methylation an emerging regulator of protein function. Molecular Cell 18:263−272

doi: 10.1016/j.molcel.2005.04.003
[65]

Casadio F, Lu X, Pollock SB, LeRoy G, Garcia BA, et al. 2013. H3R42me2a is a histone modification with positive transcriptional effects. Proceedings of the National Academy of Sciences of the United States of America 110:14894−14899

doi: 10.1073/pnas.1312925110
[66]

Si Y, Bon C, Barbachowska M, Cadet-Daniel V, Jallet C, et al. 2022. A novel screening strategy to identify histone methyltransferase inhibitors reveals a crosstalk between DOT1L and CARM1. RSC Chemical Biology 3:456−467

doi: 10.1039/d1cb00095k
[67]

Wu J, Xu W. 2012. Histone H3R17me2a mark recruits human RNA polymerase-associated factor 1 complex to activate transcription. Proceedings of the National Academy of Sciences of the United States of America 109:5675−5680

doi: 10.1073/pnas.1114905109
[68]

Chen FX, Xie P, Collings CK, Cao K, Aoi Y, et al. 2017. PAF1 regulation of promoter-proximal pause release via enhancer activation. Science 357:1294−1298

doi: 10.1126/science.aan3269
[69]

Chen FX, Woodfin AR, Gardini A, Rickels RA, Marshall SA, et al. 2015. PAF1, a molecular regulator of promoter-proximal pausing by RNA polymerase II. Cell 162:1003−1015

doi: 10.1016/j.cell.2015.07.042
[70]

Alfred Witjes J, Lebret T, Compérat EM, Cowan NC, De Santis M, et al. 2017. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. European Urology 71:462−475

doi: 10.1016/j.eururo.2016.06.020
[71]

Haas G, Fan S, Ghadimi M, De Oliveira T, Conradi LC. 2021. Different forms of tumor vascularization and their clinical implications focusing on vessel co-option in colorectal cancer liver metastases. Frontiers in Cell and Developmental Biology 9:612774

doi: 10.3389/fcell.2021.612774
[72]

Das RN, Tevet Y, Safriel S, Han Y, Moshe N, et al. 2022. Generation of specialized blood vessels via lymphatic transdifferentiation. Nature 606:570−575

doi: 10.1038/s41586-022-04766-2
[73]

Sayed N, Wong WT, Ospino F, Meng S, Lee J, et al. 2015. Transdifferentiation of human fibroblasts to endothelial cells: role of innate immunity. Circulation 131:300−309

doi: 10.1161/CIRCULATIONAHA.113.007394
[74]

Wu JY, Huang TW, Hsieh YT, Wang YF, Yen CC, et al. 2020. Cancer-derived succinate promotes macrophage polarization and cancer metastasis via succinate receptor. Molecular Cell 77:213−227.e5

doi: 10.1016/j.molcel.2019.10.023
[75]

Tannahill GM, Curtis AM, Adamik J, Palsson-McDermott EM, McGettrick AF, et al. 2013. Succinate is an inflammatory signal that induces IL-1β through HIF-1α. Nature 496:238−242

doi: 10.1038/nature11986
[76]

Guzy RD, Sharma B, Bell E, Chandel NS, Schumacker PT. 2008. Loss of the SdhB, but Not the SdhA, subunit of complex II triggers reactive oxygen species-dependent hypoxia-inducible factor activation and tumorigenesis. Molecular and Cellular Biology 28:718−731

doi: 10.1128/MCB.01338-07
[77]

Rubic T, Lametschwandtner G, Jost S, Hinteregger S, Kund J, et al. 2008. Triggering the succinate receptor GPR91 on dendritic cells enhances immunity. Nature Immunology 9:1261−1269

doi: 10.1038/ni.1657
[78]

Markovich D, Murer H. 2004. The SLC13 gene family of sodium sulphate/carboxylate cotransporters. Pflügers Archiv 447:594−602

doi: 10.1007/s00424-003-1128-6
[79]

Bertrand-Chapel A, Caligaris C, Fenouil T, Savary C, Aires S, et al. 2022. SMAD2/3 mediate oncogenic effects of TGF-β in the absence of SMAD4. Communications Biology 5:1068

doi: 10.1038/s42003-022-03994-6
[80]

Deng Z, Fan T, Xiao C, Tian H, Zheng Y, et al. 2024. TGF-β signaling in health, disease, and therapeutics. Signal Transduction and Targeted Therapy 9:61

doi: 10.1038/s41392-024-01764-w
[81]

Massagué J, Sheppard D. 2023. TGF-β signaling in health and disease. Cell 186:4007−4037

doi: 10.1016/j.cell.2023.07.036
[82]

Hua W, Ten Dijke P, Kostidis S, Giera M, Hornsveld M. 2020. TGFβ-induced metabolic reprogramming during epithelial-to-mesenchymal transition in cancer. Cellular and Molecular Life Sciences 77:2103−2123

doi: 10.1007/s00018-019-03398-6
[83]

Derynck R, Zhang YE. 2003. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 425:577−584

doi: 10.1038/nature02006
[84]

Sun X, Zhang X, Zhai H, Zhang D, Ma S. 2019. Chicoric acid (CA) induces autophagy in gastric cancer through promoting endoplasmic reticulum (ER) stress regulated by AMPK. Biomedicine & Pharmacotherapy 118:109144

doi: 10.1016/j.biopha.2019.109144